Humacyte Cost Of Revenue from 2010 to 2024

HUMAW Stock  USD 1.69  0.11  6.96%   
Humacyte Cost Of Revenue yearly trend continues to be fairly stable with very little volatility. Cost Of Revenue is likely to outpace its year average in 2024. During the period from 2010 to 2024, Humacyte Cost Of Revenue regression line of quarterly data had mean square error of 746.3 T and geometric mean of  34,712,635. View All Fundamentals
 
Cost Of Revenue  
First Reported
2010-12-31
Previous Quarter
76.5 M
Current Value
80.4 M
Quarterly Volatility
29.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Humacyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Humacyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.7 M, Interest Expense of 1.1 M or Selling General Administrative of 21.1 M, as well as many indicators such as Price To Sales Ratio of 96.95, Dividend Yield of 0.0 or PTB Ratio of 22.77. Humacyte financial statements analysis is a perfect complement when working with Humacyte Valuation or Volatility modules.
  
Check out the analysis of Humacyte Correlation against competitors.
For more information on how to buy Humacyte Stock please use our How to Invest in Humacyte guide.

Latest Humacyte's Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Humacyte over the last few years. Cost of Revenue is found on Humacyte income statement and represents the costs associated with goods and services Humacyte provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Humacyte's Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Humacyte's overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

Humacyte Cost Of Revenue Regression Statistics

Arithmetic Mean61,979,567
Geometric Mean34,712,635
Coefficient Of Variation47.23
Mean Deviation22,560,360
Median75,603,000
Standard Deviation29,271,911
Sample Variance856.8T
Range80.3M
R-Value(0.44)
Mean Square Error746.3T
R-Squared0.19
Significance0.10
Slope(2,862,020)
Total Sum of Squares11995.8T

Humacyte Cost Of Revenue History

202480.4 M
202376.5 M
20228.3 M
202149 K
20208.4 M

About Humacyte Financial Statements

Humacyte investors use historical fundamental indicators, such as Humacyte's Cost Of Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Humacyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue76.5 M80.4 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Humacyte Stock Analysis

When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.